5. EVALUATION OF LIVER AND KIDNEY FUNCTIONS IN HIV PATIENTS UNDERGOING ARV TREATMENT AT THU DUC CITY HOSPITAL DURING THE PERIOD 2023-2024 AND ASSOCIATED FACTORS
Main Article Content
Abstract
Objective: Evaluated the liver and kidney functions of HIV patients undergoing ARV at Thu Duc city Hospital during the period from 2023 to 2024 and to identify the factors associated with kidney dysfunction and elevated liver enzymes.
Methods: This retrospective, descriptive study was conducted at the Infectious Diseases Unit, Department of Internal Medicine, Thu Duc city Hospital with participating of 235 HIV patients who met the study inclusion criteria. Blood tests, including ALT, AST, and creatinine, were assessed before and one year after starting ARV treatment.
Results: The study found that after one year of ARV treatment, there was an increase in the incidence of kidney dysfunction, with the proportion of patients with normal kidney function decreasing from 74.5% to 66.8%. Additionally, the percentage of patients with elevated liver enzymes slightly increased from 11.5% to 12.8%. Gender and cardiovascular disease were statistically significant factors associated with kidney dysfunction (p < 0.05). However, no significant associations were found between other factors, such as age, location, or respiratory diseases, and liver function impairment.
Conclusion: After one year of ARV treatment, there is an increased risk of kidney dysfunction and a slight increase in liver enzyme abnormalities in HIV patients. Monitoring and managing these functions are essential during ARV therapy, especially in male patients and those with cardiovascular conditions.
Article Details
Keywords
HIV, kidney function, liver function, kidney dysfunction, elevated liver enzymes
References
[2] Price C.J, Thio L.C, Liver disease in the HIV-infected individual, Clin Gastroenterol Hepatol, 2010 Dec, 8 (12): 1002-12.
[3] Razzak-Chaudhary S, Workeneh B.T, Montez-Rath M.E, Zolopa A.R, Klotman P.E, Winkelmayer W.C, Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015 Oct, 30 (10): 1734-40.
[4] Ryom L, Mocroft A, Kirk O, Worm S.W, Kamara D.A, Reiss P et al, Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study, The Journal of infectious diseases, 2013 May 1, 207 (9): 1359-69.
[5] Kwo P.Y, Cohen S.M, Lim J.K, ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries, The American journal of gastroenterology, 2017 Jan, 112 (1): 18-35.
[6] Longenecker C.T, Scherzer R, Bacchetti P, Lewis C.E, Grunfeld C, Shlipak M.G, HIV viremia and changes in kidney function, AIDS (London, England), 2009 Jun 1, 23 (9): 1089-96.
[7] Heron J.E, Bagnis C.I, Gracey D.M, Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV, AIDS Research and Therapy, 2020, 17 (1): 11.
[8] Peluso M.J, Colby D.J, Pinyakorn S, Ubolyam S, Intasan J, Trichavaroj R et al, Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection, Journal of the International AIDS Society, 2020 Jan, 23 (1): e25444.
[9] Lucas G.M, Clarke W, Kagaayi J, Atta M.G, Fine D.M, Laeyendecker O et al, Decreased kidney function in a community-based cohort of HIV-Infected and HIV-negative individuals in Rakai, Uganda. Journal of acquired immune deficiency syndromes (1999) , 2010 Dec, 55 (4): 491-4.
[10] Neff G.W, Jayaweera D, Sherman K.E, Drug-Induced Liver Injury in HIV Patients, Gastroenterology & hepatology, 2006 Jun, 2 (6): 430-7.